Biogen to Open New Global Headquarters in Kendall Square

Biogen has announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen’s presence in Kendall Square, integrating Biogen’s R&D and technical operations teams alongside its global and North American commercial organizations into a co-located innovation hub. The new state-of-the-art facility is scheduled to open in 2028 when Biogen celebrates its 50^th anniversary.

“Nearly 50 years after first putting down roots in Kendall Square, Biogen is embarking on a new chapter in the very heart of the community that has shaped our success,” said Christopher A. Viehbacher, President and Chief Executive Officer at Biogen. “Our new space will support the advancement of our pipeline of breakthrough medicines by bringing our employees together and fostering collaboration with leading scientific minds, key partners, and top talent.”

Biogen has signed a 15-year lease for approximately 580,000-square-feet of office and R&D space as part of the Kendall Common development project. The lease agreement is with a new joint venture partnership between MIT Investment Management Company and BioMed Realty, a Blackstone Real Estate portfolio company, that is developing the new building.

Biogen plans to be the sole corporate tenant in the building, allowing the company to optimize its real estate footprint in Cambridge and create a purpose-built innovation hub designed to foster increased collaboration among employees and external partners. This state-of-the-art facility will feature laboratories of the future, upgraded workspaces, and modern amenities, along with sustainable design elements such as advanced water conservation measures and energy-efficient systems. (Source: Biogen Website, 24 March, 2025)